Downregulation of P-glycoprotein (P-gp) and Transglutaminase 2 (TG2) has been identified as a potential mechanism to sensitize drug-resistant breast cancer cells to chemotherapy [66]. The gene discussed is TGM2; the disease is breast carcinoma.